RDHL
NASD RedHill Biopharma Ltd. Sponsored ADR$0.4801 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.4801, $0.0398 below the day’s high of $0.5199
- YTD change
- -53.39%
- vs 20-day SMA
- -6.51%
- vs 200-day SMA
- -43.75%
Price ranges
Price & Performance
-0.32 (-40.14%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $14,740.0000
- RDHL is down 53% since the beginning of the year
- RDHL is down 69% over the past 12 months
- RDHL is down 19% over the past 1 month
- 1% of all RDHL investors are betting against RDHL
RDHL reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -68.0%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0041
- Last 5 days
- -16.94%
- vs 8-day SMA
- -6.52%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
